Fesoterodine: Difference between revisions

Jump to navigation Jump to search
m (Protected "Fesoterodine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
 


The [[antimuscarinic]] [[Fesoterodine]] is a drug developed by [[Schwarz Pharma AG]] to treat [[Overactive bladder syndrome]].<ref>{{cite web| url=http://www.medicalnewstoday.com/articles/41688.php| title=Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights| date=[[17 April]] [[2006]]|publisher=[[Medical News Today]]}}</ref> It was recommended for approval by the [[European Medicines Agency]] in February 2007, but is not yet available for use.{{Fact|date=November 2007}}
The [[antimuscarinic]] [[Fesoterodine]] is a drug developed by [[Schwarz Pharma AG]] to treat [[Overactive bladder syndrome]].<ref>{{cite web| url=http://www.medicalnewstoday.com/articles/41688.php| title=Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights| date=[[17 April]] [[2006]]|publisher=[[Medical News Today]]}}</ref> It was recommended for approval by the [[European Medicines Agency]] in February 2007, but is not yet available for use.{{Fact|date=November 2007}}
Line 7: Line 7:
{{reflist}}
{{reflist}}


{{SIB}}
 


[[Category:Muscarinic antagonists]]
[[Category:Muscarinic antagonists]]

Revision as of 02:40, 9 August 2012

WikiDoc Resources for Fesoterodine

Articles

Most recent articles on Fesoterodine

Most cited articles on Fesoterodine

Review articles on Fesoterodine

Articles on Fesoterodine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fesoterodine

Images of Fesoterodine

Photos of Fesoterodine

Podcasts & MP3s on Fesoterodine

Videos on Fesoterodine

Evidence Based Medicine

Cochrane Collaboration on Fesoterodine

Bandolier on Fesoterodine

TRIP on Fesoterodine

Clinical Trials

Ongoing Trials on Fesoterodine at Clinical Trials.gov

Trial results on Fesoterodine

Clinical Trials on Fesoterodine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fesoterodine

NICE Guidance on Fesoterodine

NHS PRODIGY Guidance

FDA on Fesoterodine

CDC on Fesoterodine

Books

Books on Fesoterodine

News

Fesoterodine in the news

Be alerted to news on Fesoterodine

News trends on Fesoterodine

Commentary

Blogs on Fesoterodine

Definitions

Definitions of Fesoterodine

Patient Resources / Community

Patient resources on Fesoterodine

Discussion groups on Fesoterodine

Patient Handouts on Fesoterodine

Directions to Hospitals Treating Fesoterodine

Risk calculators and risk factors for Fesoterodine

Healthcare Provider Resources

Symptoms of Fesoterodine

Causes & Risk Factors for Fesoterodine

Diagnostic studies for Fesoterodine

Treatment of Fesoterodine

Continuing Medical Education (CME)

CME Programs on Fesoterodine

International

Fesoterodine en Espanol

Fesoterodine en Francais

Business

Fesoterodine in the Marketplace

Patents on Fesoterodine

Experimental / Informatics

List of terms related to Fesoterodine


The antimuscarinic Fesoterodine is a drug developed by Schwarz Pharma AG to treat Overactive bladder syndrome.[1] It was recommended for approval by the European Medicines Agency in February 2007, but is not yet available for use.[citation needed]

References

  1. "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. Check date values in: |date= (help)

Template:WH Template:WikiDoc Sources